Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Transitional Cell × bicalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7 Stage I Prostate Adenocarcinoma 1 Neoplasm Metastasis 1 Glioma 1 Glioblastoma 1 Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 6 avelumab 4 Magnetic Resonance Spectroscopy 2 Docetaxel 2 Cisplatin 2 ALT-803 2 yeast-CEA vaccine 1 vadimezan 1 trebananib 1 obinutuzumab 1 naptumomab estafenatox 1 erdafitinib 1 enfortumab vedotin 1 bicalutamide 1 atezolizumab 1 Ultrasonography 1 Specimen Handling 1 Ramucirumab 1 Radiosurgery 1 Phantoms, Imaging 1 PM 01183 1 Omacor 1 Neoadjuvant Therapy 1 Mitomycin 1 Lycopene 1 Leucovorin 1 High-Intensity Focused Ultrasound Ablation 1 Gemcitabine 1 Fulvestrant 1 Fluorouracil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡